Neptune Receives TSX Conditional Approval

Thu Oct 27, 2011 10:40am EDT

* Reuters is not responsible for the content in this press release.

LAVAL, Quebec, Oct. 27, 2011 (GLOBE NEWSWIRE) -- Neptune Technologies and
Bioressources Inc. (Nasdaq:NEPT) (TSX-V:NTB) is pleased to announce that it has
received conditional approval for a listing of its common shares on the Toronto
Stock Exchange (TSX) under the same symbol, ''NTB''.

Upon filing and acceptance of the final listing application and related
documentation, the Company's shares will commence trading on the Toronto Stock
Exchange and be de-listed from the TSX Venture Exchange. The Company anticipates
its listing date to be before the end of 2011.

Henri Harland, President & CEO, stated ''I would like to thank the Toronto Stock
Exchange for its consideration, and conditional acceptance for listing on
Canada's senior stock exchange which will facilitate access to larger pools of
growth capital and create greater liquidity. This event marks another
significant milestone reflecting the growth of Neptune over the last few

About Neptune Technologies & Bioressources Inc.

Neptune is an industry-recognized leader in the innovation, production and
formulation of science-based and clinically proven novel phospholipid products
for the nutraceutical and pharmaceutical markets. The Company focuses on growing
consumer health markets including cardiovascular, inflammatory and neurological
diseases driven by consumers taking a more proactive approach to managing health
and preventing disease. The Company sponsors clinical trials aimed to
demonstrate its product health benefits and to obtain regulatory approval for
label health claims. Neptune is continuously expanding its intellectual property
portfolio as well as clinical studies and regulatory approvals. Neptune's
products are marketed and distributed in over 20 countries worldwide.

About Acasti Pharma Inc.

Acasti Pharma (TSX-V:APO) is developing a product portfolio of proprietary novel
long-chain omega-3 phospholipids. Phospholipids are the major component of cell
membranes and are essential for all vital cell processes. They are one of the
principal constituents of High Density Lipoprotein (good cholesterol) and, as
such, play an important role in modulating cholesterol efflux. Acasti Pharma's
proprietary novel phospholipids carry and functionalize the polyunsaturated
omega-3 fatty acids EPA and DHA, which have been shown to have substantial
health benefits and which are stabilized by astaxanthin, a potent antioxidant.
Acasti Pharma is focusing initially on treatments for chronic cardiovascular and
cardiometabolic conditions within the over-the-counter, medical food and
prescription drug markets.

About NeuroBioPharm Inc.

NeuroBioPharm is pursuing pharmaceutical neurological applications, and a
clinical study for a medical food product with a multinational partner is
already initiated. The development of a prescription drug candidate is currently
in progress. Advanced clinical development and commercialization is planned to
be carried out with multinational partners.

"Neither Nasdaq nor the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release."

Statements in this press release that are not statements of historical or
current fact constitute "forward-looking statements" within the meaning of the
U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities
laws. Such forward-looking statements involve known and unknown risks,
uncertainties, and other unknown factors that could cause the actual results of
the Company to be materially different from historical results or from any
future results expressed or implied by such forward-looking statements. In
addition to statements which explicitly describe such risks and uncertainties,
readers are urged to consider statements labeled with the terms "believes,"
"belief," "expects," "intends," "anticipates," "will," or "plans" to be
uncertain and forward-looking. The forward-looking statements contained herein
are also subject generally to other risks and uncertainties that are described
from time to time in the Company's reports filed with the Securities and
Exchange Commission and the Canadian securities commissions.

CONTACT: Neptune Contact:
         Neptune Technologies & Bioressources Inc.
         Andre Godin, CFO

         CEOcast Contact:
         Dan Schustack
         +1 212-732-4300

         Howard Group Contact:
         Dave Burwell
         (888) 221-0915
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.